Study on FGFR2/3 Inhibitor (CGT4859) for Patients with Cholangiocarcinoma and Other Advanced Solid Tumors

Inclusion Criteria

• Have a confirmed diagnosis of advanced or metastatic cholangiocarcinoma or another solid tumor with specific FGFR2 or FGFR3 genetic changes.
• Have already tried standard treatments, are not suitable for them, or have chosen not to undergo them.
• Have at least one tumor that can be measured by scans.
• Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have acceptable blood test results within specified limits.
• Have recovered from any side effects of previous treatments to a mild level, except for hair loss, controlled hypothyroidism, type 1 diabetes, or nail infections managed with local treatment.

Exclusion Criteria

• Have received chemotherapy, other cancer treatments, or radiation therapy within a certain period before starting the study drug.
• Have had major surgery, like abdominal surgery, within 4 weeks before starting the study drug.
• Have significant eye problems affecting the cornea or retina, or current retinal detachment.
• Have received more than two previous treatments targeting FGFR.
• Have active, symptomatic, or untreated brain tumors unless stable and not needing steroids for at least 2 months.